CLPT · ClearPoint Neuro, Inc. · Stock research

Current Thesis

ClearPoint sells the delivery infrastructure for CNS gene therapy — the SmartFlow cannula and MRI/iCT-guided navigation that partner programs use to put a molecule into the brain — so it earns off the build-out regardless of which therapy clears first. The narrative re-rated in mid-June on two uniQure prints, both administered through ClearPoint hardware: a 2026-06-17 plan to file the AMT-130 Huntington's BLA in the Q3-2026 window, and 2026-06-19 first-cohort AMT-260 epilepsy data. Three weeks on, the setup has cooled. The theme registry now tags the name to life-sciences tools/diagnostics alone, the gene-therapy leg having downshifted from accelerating to maturing, and there is no dated company-specific catalyst before the mid-August Q2 print. The last validated tape ($18.72 on 2026-07-02) held the 6/18 gap and modestly extended, which reads as consolidation on the breakout shelf. That makes this a base to watch, not a momentum entry: the binary that drove the re-rate has already printed, and the next hard date is an earnings event the thesis does not depend on.

Bullish and bearish views on ClearPoint Neuro, Inc.

The model's bull view on ClearPoint Neuro, Inc. (CLPT), in brief: Q1 2026 record revenue $12.1M, +43% YoY (16% organic), reported 2026-05-13; FY2026 guide reaffirmed at $52–56M; gross margin 64%, up from 60%. The bear view: The catalysts that mattered have already printed: the AMT-130 BLA plan (2026-06-17) and AMT-260 data (2026-06-19) are public, the theme has downshifted to maturing, and no dated company-specific catalyst falls inside the next 30 days. Both cases follow in full.

Bull Case

• Q1 2026 record revenue $12.1M, +43% YoY (16% organic), reported 2026-05-13; FY2026 guide reaffirmed at $52–56M; gross margin 64%, up from 60%.
• uniQure AMT-130 Huntington's: 3-year high-dose data showed 75% slowing of cUHDRS progression versus propensity-matched external controls; in a Type B meeting disclosed 2026-06-17 the FDA accepted that 3-year analysis as the primary basis for an accelerated-approval BLA targeted for the Q3-2026 window, with RMAT, Breakthrough and Fast Track in hand. AMT-130 is administered via ClearPoint navigation/SmartFlow, so a first approved CNS gene therapy seeds a per-procedure delivery line.
• AMT-260 epilepsy preliminary data (2026-06-19): 3 of 6 low-dose patients posted 79–100% reductions in disabling seizures across months 4–6 with no therapy- or surgery-related SAEs — a second ClearPoint-delivered program stays live.
• Installed base of 175+ global centers as of the 2026-05-13 update; capital-equipment and software revenue +177% YoY to $1.4M widens the razor base that pulls recurring disposables.
• 60+ biopharma partners; a 10-year focused-ultrasound development partnership with Sungkyunkwan University (2026-05-27) extends the ecosystem into blood-brain-barrier delivery, and the Velocity Alpha MR surgical drill cleared FDA 510(k) (2026-04-22) and CE Mark (2026-05-13).
• The Oberland note facility carries additional $25M and $50M tranches drawable before 2026-12-31 — committed capital that lowers the odds of a forced dilutive equity raise.
• B. Riley kept a Buy and lifted its target to $30 on 2026-06-18; the 3-analyst average target is $22.44. The last print of $18.72 (2026-07-02) sits under both, leaving analyst-defined headroom intact.

Bear Case

• The catalysts that mattered have already printed: the AMT-130 BLA plan (2026-06-17) and AMT-260 data (2026-06-19) are public, the theme has downshifted to maturing, and no dated company-specific catalyst falls inside the next 30 days.
• The AMT-260 read was thin — 3 of 6 low-dose patients responded strongly, and the higher-dose cohort update is not due until H1 2027, a long wait for the next data point.
• The FDA still has to align with uniQure on confirmatory-study design (a concurrent standard-of-care control rather than a sham procedure) before the BLA — a gating step that can push a soft Q3-2026 filing further right.
• Cash was $35.6M at 3/31/26 against ~$8M/quarter operating burn; an S-3 shelf is on file, so equity-raise optionality is a standing overhang even with the Oberland debt tranches available.
• The name trades as a uniQure sympathy proxy — the 6/18 +26% gap to a $16.81 close came off partner news, not ClearPoint's own results — so a QURE disappointment or FDA setback hits this tape harder than the delivery fundamentals justify.
• The mid-August Q2 print is a binary the thesis does not require, and stepping in ahead of it stacks earnings risk on top of an already-maturing setup.

Setup & Price Structure

• Most recent validated print $18.72 (2026-07-02); this reference is now 3+ weeks old and should be re-checked against live quotes before acting on any level here.
• Structure: the 2026-06-18 session gapped +26% to a $16.81 close on the QURE read, then held and modestly extended above that gap through early July — consolidation on the breakout shelf rather than a distribution top.
• A weekly close below $16 loses that shelf and unwinds the June re-rate. Overhead reference sits at the $22.44 consensus average and the $30 B. Riley target.
• Momentum ran hot into the June spike (RSI in the mid-70s on the gap day) and has since had three weeks to cool; a fresh entry no longer rides an accelerating tape, and there is no clean higher-low pullback-to-support trigger on the board yet.
• Liquidity is small-cap and headline-driven; gaps on partner news are the dominant price mechanism, so any sizing has to assume overnight event risk.

Catalyst Calendar (next 30 days)

• ~2026-08-13 (est.): Q2 2026 earnings. Q1 landed 2026-05-13, so the June-quarter report is the one dated event inside the window. Watch the FY2026 $52–56M guide, the gross-margin trend off the Q1 64%, cash burn against the $35.6M base, and any capital-raise language. Binary risk for a thesis that is not earnings-driven — reason to let the print pass rather than enter into it.
• Q3-2026 (undated, soft): uniQure AMT-130 Huntington's BLA submission — the master catalyst, contingent on FDA confirmatory-study-design alignment. No confirmed date; a formal BLA acceptance would be the re-acceleration trigger.
• No AMT-260 update expected in-window; the higher-dose epilepsy cohort read is not due until H1 2027.

What Would Change Our Mind

• Bearish invalidation: a weekly close below $16 breaks the post-catalyst breakout shelf and unwinds the June re-rate; reinforced if the AMT-130 BLA slips out of the Q3-2026 window or draws an FDA refuse-to-file, or if the FY2026 revenue guide is cut below the $52M floor at the Q2 print.
• Bullish re-acceleration that would turn a base-watch into an entry: a dated AMT-130 BLA acceptance, a fresh uniQure Huntington's or epilepsy data/regulatory beat, or a Q2 print that raises the FY2026 guide and clears the dilution overhang. Any of these would re-tag the gene-therapy leg toward accelerating and justify sizing up on a clean higher-low.

Correlation Notes

• Primary driver is uniQure (QURE): CLPT moves on AMT-130/AMT-260 trial and FDA headlines more than on its own results, so QURE is the leading indicator for this tape.
• Beta to the broader CNS gene-therapy and life-sciences-tools/diagnostics complex; focused-ultrasound and neuro-delivery peers share the theme.
• Small-cap medtech liquidity means index and risk-on/risk-off swings amplify single-name gaps; an S-3 shelf on file adds idiosyncratic supply risk on any strength.